{"title": "Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents", "abstract": "", "autors": [{"firstname": "Donald", "middlename": "F", "surname": "Smee"}, {"firstname": "Justin", "middlename": "G", "surname": "Julander"}, {"firstname": "E", "middlename": "", "surname": "Bart Tarbet"}, {"firstname": "Matthew", "middlename": "", "surname": "Gross"}, {"firstname": "Jack", "middlename": "", "surname": "Nguyen"}], "blocks": [{"title": "Introduction", "sequence": "1.", "paragraphs": [["Virus resistance to neuraminidase inhibitors has become the subject of increasing concern, based upon a higher frequency of isolating such viruses from infected patients.", "Fortunately, the 2009 H1N1 virus was sensitive to oseltamivir, although it was completely resistant to the drugs amantadine and rimantadine.", "An analysis of treatment benefit during the pandemic indicated that oseltamivir initiated prior to the first 48 h reduced morbidity and mortality in severe cases.", "In addition, prophylaxis of individuals in contact with influenza-afflicted persons provided significant protection from infection.", "As the pandemic progressed and treatments with oseltamivir were given, some oseltamivir-resistant viruses were isolated and characterized E-mail address: don.smee@usu.edu."], [".", "The predominant mutation conferring resistance to oseltamivir was in the viral neuraminidase at position 275 where histidine was replaced by tyrosine.", "However, the overall incidence of oseltamivir -resistant virus isolation was only about 1% of isolates.", "This situation could change from year to year, based upon finding up to 68% of virus isolates resistant to oseltamivir prior to 2009.", "The effectiveness of treatment of oseltamivir-resistant H1N1 H275Y virus infections has been shown to be reduced in pediatric clinical settings.", "A fatal case of oseltamivir-resistant H1N1 H275Y virus infection was recently reported from Korea, underscoring the virulence potential of the resistant virus."], ["Animal models, particularly mice and to a lesser extent ferrets, are routinely used to study treatment of influenza virus infections with existing drugs or new compounds   infection model in mice.", "Note that prior to 2009 the convention for identifying amino acids in the viral neuraminidase followed H3N2 numbering, which differs in initial length from H1N1 by one amino acid.", "Thus, all earlier H1N1 viruses with an H275Y mutation were referred to as H274Y. In the present article the viruses are all referred to as H275Y."], ["The H275Y virus that was used for the studies of Baz and others was created by genetic engineering.", "Oseltamivir was found to be ineffective in treating the infection when administered up to 10 mg/kg/day.", "However, an experimental neuraminidase inhibitor, A-322278, did show some efficacy in treating this infection.", "In that study the efficacy of higher doses of oseltamivir were not determined.", "Yen and colleagues engineered an influenza A/Vietnam/ 1203/2004 virus with an H275Y mutation that conferred oseltamivir resistance and yet retained lethality in mice.", "Antiviral studies with this virus have not been reported.", "We are not aware of any influenza A or influenza B viruses adapted to mice that are resistant to oseltamivir."], ["The H1N1 virus that emerged in 2009 was found to be lethal in mice following adaptation, and some virus isolates were even able to because mortality without adaptation in certain strains of mice.", "The influenza A/California /04/2009 virus that was mouse adapted had the following mutations compared to wild-type virus: 1 in PB2, 3 in HA genes.", "Later, certain oseltamivir-resistant H1N1 viruses were isolated and found to because disease in mice and ferrets.", "It is possible that these isolates may be appropriate for antiviral studies in animals."], ["The purpose of this work was to develop an oseltamivir-resistant virus suitable for chemotherapy experiments in mice, and then to determine its susceptibility in the mouse model to various antiviral agents.", "Our efforts began prior to the emergence of the 2009 pandemic and before the published work of Baz et al. with the genetically engineered influenza A/WSN/33 H275Y virus.", "Because we were aware that mouse-adapted strains might only produce partially lethal infections in mice, several strains of virus were investigated.", "The viruses that we used were those that became available to us for research purposes.", "We determined that a mouse-adapted influenza A/Mississippi/03/ 2001 was consistently lethal to BALB/c mice in repeated experiments.", "A pandemic virus resistant to oseltamivir, A/Hong Kong/2369/2009, was acquired by us and subsequently adapted for lethality in mice.", "Another virus strain serially passaged in mice, influenza A/Hawaii/21/2007 H275Y, was found to only be partially lethal to the animals, and no further work was done with that virus."], ["In the present studies we demonstrate the efficacy of several influenza virus inhibitors over a range of doses in mice lethally infected with the A/MS-H275Y and the A/HK-H275Y viruses.", "Infections of mice with these novel mouse adapted strains, particularly A/MS-H275Y, will be useful as models for studying treatment regimens that may combat oseltamivir-resistant virus infections."]]}, {"title": "Materials and methods", "sequence": "2.", "paragraphs": []}, {"title": "Antiviral compounds", "sequence": "2.", "paragraphs": [["Amantadine and rimantadine were purchased from Sigma (St."], ["Louis, MO, USA).", "Oseltamivir phosphate.", "All compounds, except zanamivir, were prepared in water for oral gavage treatment of mice.", "Water served as the oral gavage placebo.", "Zanamivir was prepared in sterile saline for intraperitoneal injection, and sterile saline served as the placebo for studies with zanamivir in mice.", "Because oseltamivir was used from pharmaceutical capsules that also contained excipients, the entire contents of 75 mg capsules minus the she will were added to water to make up the highest mg/kg/day dose.", "Lower doses of oseltamivir were prepared by dilution.", "We have previously reported that oseltamivir from Tamiflu capsules performs similar to oseltamivir phosphate in mice."]]}, {"title": "Viruses", "sequence": "2.", "paragraphs": [["Influenza A/MS-H275Y was obtained from the Neuraminidase Inhibitor Surveillance Network.", "The virus was passaged seven times in mice to enhance its virulence, then once in Madin-Darby canine kidney cells.", "Influenza A/HK-H275Y virus was provided by Kwok-Yung Yuen, The University of Hong Kong, Hong Kong Special Administrative Region, People s Republic of China.", "This was one of the first reported oseltamivir-resistant pandemic viruses.", "The virus was adapted to mice by four sequential passages through mouse lungs, followed by one passage in MDCK cells.", "For passaging, BALB/c mice were infected with a 90-ll suspension of virus at a 1:2 dilution of the previously derived virus pool, starting with virus propagated in MDCK cells.", "Lungs were harvested from the mice at three days post-infection, homogenized in cell culture medium and frozen for subsequent passage in mice."], ["The mouse-adapted viruses were partially sequenced in the neuraminidase gene and found to contain the H275Y mutation, as did the parental viruses.", "No other genes were sequenced."]]}, {"title": "Viral cytopathic effect inhibition assay", "sequence": "2.", "paragraphs": [["MDCK cells in 96-well microplates were infected with approximately 50 cell culture infectious doses of virus.", "The medium used for assays was MEM, 0.22% sodium bicarbonate, and 10 units/ml of trypsin.", "Compounds in half-log10 concentrations were applied to cells 5 10 min prior to adding virus-containing medium.", "Three microwells at each concentration of compound were infected.", "Two microwells were uninfected and served as toxicity controls.", "After three days of incubation in 5% CO2 at 37 C, CPE was quantified by neutral red dye uptake using the dye at a 0.011% final concentration for 2 h. Excess dye was rinsed from cells with PBS.", "The absorbed dye was eluted from the cells with 0.1 ml of 50% S rensen s citrate buffer /50", "% ethanol.", "Plates were read for optical density determination at 560 nm.", "Readings were converted to percent of uninfected control using an Excel spread sheet developed for this purpose.", "Fifty percent virus-inhibitory concentrations and 50% cytotoxic concentrations were determined by plotting percent CPE versus log10 of inhibitor concentration.", "Selectivity index values were calculated as CC50/EC50. !", "D.F. Smee and others / Antiviral Research 96 13 20 15"]]}, {"title": "Viral neuraminidase inhibition assay", "sequence": "2.", "paragraphs": [["The effects of compounds on viral neuraminidase activity were determined using a commercially available kit   for 0.5 s immediately after addition of NA-Star accelerator solution.", "Fifty percent inhibitory concentrations were determined by plotting percent chemiluminescent counts versus log10 inhibitor concentration."]]}, {"title": "Animal experiment design", "sequence": "2.", "paragraphs": [["Female BALB/c mice were anesthetized by intraperitoneal injection of ketamine/xylazine, followed by intranasal infection with a 90-ll suspension of influenza virus.", "The virus challenge was approximately three 50% mouse lethal infectious doses and equated to approximately 1 3 x 104 50% cell culture infectious doses per mouse.", "Other investigators use lower.", "There were 10 mice per antiviral compound dosage group.", "Twenty placebo-treated mice were used in studies with amantadine, oseltamivir, and ribavirin, whereas the rimantadine and zanamivir experiments each had 15 placebos."], ["For one experiment the lungs from sacrificed mice were assayed for virus titer.", "This was performed by harvesting the lungs   on days 3 and 6 after infection.", "Lungs were weighed, then frozen at80 C. Later, thawed lungs were homogenized and samples plated in quadruplicate on MDCK cell monolayers in 96-well microplates in 10-fold dilution increments.", "On day 6 of the infection of cells, wells were observed microscopically for the appearance of viral cytopathic effect.", "Endpoint dilution ti ters were calculated, and results converted to log10 cell culture infectious doses per gram of tissue."]]}, {"title": "Statistical analysis of animal studies", "sequence": "2.", "paragraphs": [["Kaplan Meier survival curves were generated and compared by the Mantel-Cox log-rank test to determine statistical significance.", "Subsequently, pairwise comparisons were made by the Gehan-Breslow -Wilcoxon test with Bonferroni-corrected threshold for significance.", "Lung virus titers were analyzed by one-way ANOVA followed by Neuman-Keuls Multiple Comparison Test.", "Pairwise comparisonswere made between drug-treatedand placebo groups, and were analyzed using Prism 5.0 software."]]}, {"title": "Ethics statement for animal studies", "sequence": "2.", "paragraphs": [["The experiments were conducted in accordance with an approved protocol by the Institutional Animal Care and Use Committee of Utah State University.", "The work was performed in the AAALAC-accredited Laboratory Animal Research Center of the university in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals."]]}, {"title": "Results", "sequence": "3.", "paragraphs": []}, {"title": "Viral cytopathic effect inhibition studies", "sequence": "3.", "paragraphs": [["Six compounds representing different classes, were evaluated for antiinfluenza virus activity in cell culture against oseltamivir-sensitive influenza A/California/07/2009 virus, and oseltamivirresistant influenza A/MS-H275Y and A/HK-H275Y viruses.", "Against the sensitive virus, the three neuraminidase inhibitors showed similar inhibitory activity of 0.04 0.08 lM, with ribavirin activity at 28 lM, and amantadine and rimantadine showing no antiviral effect.", "Against the H275Y viruses, oseltamivir carboxylate was inactive at 100 lM, peramivir exhibited protection at about 8 lM, and zanamivir was inhibitory at 0.24 0.36 lM. Amantadine and rimantadine were both highly active against A/MS-H275Y, but were not active against A/HK-H275Y. Ribavirin was inhibitory at 25 33 lM. These values are comparable to the published values against the non-mouse-adapted influenza A/MS-H275Y virus."]]}, {"title": "Viral neuraminidase inhibition experiments", "sequence": "3.", "paragraphs": [["The three inhibitors of viral neuraminidase were tested for inhibitory activity against one oseltamivir-sensitive and two oseltamivir -resistant.", "Oseltamivir carboxylate was ineffective against the two H275Y enzymes at 100 nM. Peramivir showed activity at 29 38 nM. Zanamivir was highly active at 0.9 1 nM against the drug-resistant viruses.", "Against the wild-type A/California/07/2009 virus, all three compounds were active, although oseltamivir carboxylate was slightly less potent than the other two compounds."]]}, {"title": "Efficacy of neuraminidase inhibitors in infected mice", "sequence": "3.", "paragraphs": [["Oseltamivir and zanamivir were evaluated for efficacy against influenza A/MS-H275Y virus infections in mice.", "Treatments were initiated either 2 h prior to virus challenge or 24 h after infection.", "In the 2 h infection, oseltamivir was partially protective at 100 and 300 mg/kg/day, with survival rates of 30% and 60%, respectively.", "Lower doses of oseltamivir were not active.", "When treatment initiation time was delayed to +24 h, all doses of oseltamivir were ineffective.", "Treatment with zanamivir starting at 2 h provided protection of 20%, 30%, 60%, and 90% at doses of 3, 10, 30, and 100 mg/kg/day.", "The 1-mg/kg/day dose of zanamivir was ineffective.", "Considerably less activity was observed for the +24 h treatments.", "The 100-mg/kg/day dose of zanamivir delayed the time to death significantly but did little to prevent mortality.", "Thus, neither oseltamivir nor zanamivir were able to treat an established infection."]]}, {"title": "Efficacy of M2 channel inhibitors in infected mice", "sequence": "3.", "paragraphs": [["Amantadine and rimantadine were tested for their ability to prevent or delay the time to death in mice challenged with the A/MS-H275Y virus.", "Doses of amantadine initiated at 2 h were 80 100% protective, with no effect seen at 3 mg/kg/day.", "Some activity was lost by delaying treatment to +24 h.", "The 30 and 100 mg/kg/day doses were 60% and 100% protective, respectively.", "No significant effect was seen at 3 and 10 mg/kg/day compared to placebo.", "Rimantadine provided a survival benefit at 10 and 30 mg/kg/day, starting either at 2 or +24 h, with no significant effect at 1 and 3 mg/kg/ day.", "Survival observed was between 70% and 100%, although in these experiments the placebo groups had a survival rate of 20%.", "Both amantadine and rimantadine were able to treat the infection after its onset."]]}, {"title": "Efficacy of ribavirin in infected mice", "sequence": "3.", "paragraphs": [["The protective activity of ribavirin was studied in mice infected with influenza A/MS-H275Y virus.", "Treatment efficacy was similar for treatments initiated either at 2h or at +24 h, although there were more survivors at 30 mg/kg/day in the 2 h group.", "Ribavirin was not effective at 3 and 10 mg/kg/day.", "At the higher doses, ribavirin was capable of treating the infection after it was initiated."]]}, {"title": "Efficacy of oseltamivir and ribavirin against influenza A/HK-H275Y virus infection in mice", "sequence": "3.", "paragraphs": [["Oseltamivir and ribavirin were used to treat an A/HK-H275Y virus infection starting treatment at 2 h relative to virus challenge.", "Oseltamivir was partially protective at 100 and 300 mg/kg/day, with survival rates of 50% and 70%, respectively.", "Doses of 3 and 10 mg/kg/day were not significantly effective compared to placebo.", "Ribavirin was fully protective at 75 mg/kg/day.", "These survival results for oseltamivir treatment were similar to those obtained in treating the A/MS-H275Y virus infection.", "Body weights were determined during the A/HK-H275Y virus infection.", "Weight decline was least severe in the Oseltamivir carboxylate Peramivir Zanamivir >100 10.5 1.3 D.F. Smee and others / Antiviral Research 96 13 20 ribavirin group, with weight gain starting after day 8 of the infection.", "Body weights in mice treated with oseltamivir at 100 and 300 mg/kg/day did not fall as rapidly as in the lower dosage and placebo groups.", "Body weights in these groups began to increase after day 10."], ["Lung virus titers from infected mice were determined on days 3 and 6 of the infection.", "On day 3, only ribavirin treatment significantly reduced virus titers compared to placebo.", "Virus titers in the ribavirin treatment group were not significantly lower than placebo on day 6, however."]]}, {"title": "Discussion", "sequence": "4.", "paragraphs": [["In this report we demonstrated that two different influenza A viruses possessing the H275Y mutation in the neuraminidase gene could be mouse adapted to because fatal infections in mice.", "The H275Y mutation was stable during the mouse passages, as determined by genetic analysis of the relevant region of the neuraminidase gene.", "The viruses were also evaluated in cell culture and neuraminidase assays to demonstrate that they were phenotypically resistant to oseltamivir.", "The mouse infection models were then used to demonstrate antiviral activities of several known-active antiviral agents.", "This is not the first time that antiviral studies in mice were performed with oseltamivir-resistant viruses.", "The first study that we are aware of was that of Baz and others using a recombinant influenza A/WSN/33 H275Y virus.", "In that report, they evaluated oseltamivir and a novel inhibitor, A322278.", "Oseltamivir was only used up to 10 mg/kg/day, giving a mortality rate of 75%.", "We used higher doses of the drug and saw survival rates of 30 50% at 100 mg/kg/day and 60 70% at 300 mg/kg/day.", "It is not known whether the A/WSN/33 H275Y virus reported by Baz and others would perform the same as our viruses in infected mice if treated with higher doses of oseltamivir.", "This report differs from that of Baz and colleagues in showing antiviral activities of amantadine, rimantadine, ribavirin, and zanamivir, which to our knowledge has never been shown before in a mouse model of oseltamivir-resistant virus infection."]]}, {"title": "D.F. Smee and others / Antiviral Research 96 13 20", "sequence": "18", "paragraphs": [["The cell culture studies demonstrated that the A/MS-H275Y and A/HK-H275Y viruses were resistant to oseltamivir, showed decreased sensitivity to peramivir, and were highly sensitive to zanamivir.", "The A/MS-H275Y virus was also inhibited by amantadine and rimantadine whereas the A/HK-H275Y was resistant to the adamantanes.", "Ribavirin was the least potent in cell culture of the compounds tested.", "The relative potencies identified for these compounds in vitro are similar to published reports for oseltamivir, zanamivir, and is attributable to an S31N mutation in the M2 gene."], ["Using a neuraminidase inhibition assay method, the relative inhibitory concentrations of oseltamivir carboxylate, peramivir, and zanamivir compared well with published H1N1 virus results.", "Nguyen and others tested the same strain of influenza A/HK-H275Y virus that we used with the NA-Star assay, and reported IC50 values of 78, 9.2, and 0.43 lM for oseltamivir carboxylate, peramivir, and zanamivir, respectively.", "This compares to our data of >100, 29, and 0.9 lM, respectively.", "The same pattern of antiviral potency exhibited by the compounds   was evident for both the A/MSH275Y and A/HK-H275Y viruses.", "This was not unexpected since both viruses contain the same oseltamivir-resistance mutation."], ["The choice of doses used for animal studies was based largely upon our previous experience in animal models, as well as anticipated outcomes based upon the cell culture and neuraminidase assay results.", "With oseltamivir, we wanted to administer high enough doses to find activity.", "In our animal models we rarely exceed 300 mg/kg/day with any compound, since such high doses in humans may not be tolerated.", "There are also problems with solubility, availability, and/or cost, depending upon the compound.", "Zanamivir was administered only up to 100 mg/kg/day because it showed better in vitro activity than oseltamivir carboxylate, and it was expected to perform better than oseltamivir.", "Our experience with amantadine indicated that it should be very effective at 100 mg/kg/day against the amantadine-sensitive virus   proved to be more effective than oseltamivir at the same dose.", "This is not surprising since the virus was oseltamivir-resistant and zanamivir-sensitive.", "Amantadine s 100% protective activity at the highest dose against the A/MS-H275Y virus infection was similar to that seen previously.", "Lower doses of rimantadine were as effective as the higher doses of amantadine, which correlated with the in vitro potency of each compound.", "The 75-mg/kg/day dose of ribavirin protected 90 100% of mice from death.", "In addition, weight loss data for treatments were largely dose-responsive, as have been reported in other influenza virus infections."], ["It has only been the more recent 2009 strains of oseltamivirresistant influenza virus that have been reported to be lethal to mice.", "Prior to this, only the genetically engineered A/WSN/33 H275Y viruses had been reported to lethally infect mice.", "Ilyushina and colleagues reported five amino acid changes following adaptation of influenza A/California/04/2009 wild-type virus to mice.", "These changes were in PB2, HA and NP, with none in NA.", "One of the HA mutations, D225G, was associated with increased virulence in mice.", "No other comparisons between influenza A/", "HK/2369/2009 viruses could be made due to lack of sequence data for the latter virus."], ["Experimental data suggest that fitness of influenza viruses carrying neuraminidase mutations conferring drug resistance may differ (Baz and others, 2010;Herlocher and others, 2002;Yen et al., 2007Yen et al., , 2005.", "Virulence in a mouse model may vary depending upon several factors such as location of the mutation, virus genetic back-D.F. Smee and others / Antiviral Research 96 13 20 19 ground, existence of permissive secondary neuraminidase mutations, degree of neuraminidase functional loss, and an appropriate balance between neuraminidase and hemagglutinin.", "This cannot be determined in advance without going through the process of mouse adaptation and lethality determinations, as was done for the present studies."], ["Because antiviral protection was seen with oseltamivir at high doses in the mouse models of A/MSH275Y and A/HK-H275Y virus infections, we are not suggesting that this could translate into protection against oseltamivir-resistant virus infections in humans.", "This is because the doses that were used in mice exceed the approved human dose of oseltamivir.", "In work performed at Adamas Pharmaceuticals.", "Thus, our results in mice treated with low doses of oseltamivir correlate with clinical findings.", "As a side note, ribavirin at 27 mg/kg/day and amantadine at 46 mg/kg/day in mice gave approximate human equivalent doses.", "In general, a dose in mice is 12 times that of a human for equivalency, based upon body surface area."], ["Delaying treatment by even one day is somewhat analogous to infecting with virus at a higher multiplicity of infection, thus making the infection more difficult to treat.", "Influenza virus strains vary in their ability to be treated after the infection has been initiated.", "Oseltamivir treatment of an influenza A/NWS/33 virus infection can be effective even when initiated up to three days after infection.", "Treatment of influenza H3N2 and H5N1 virus infections did not provide sufficient protection with even a oneday delay of treatment initiation, as occurs with the A/MS-H275Y and A/HK-H275Y virus infections.", "We have been investigating possible reasons for these differences but have not yet come to any conclusions.", "Other researchers have investigated differences among H5N1 virus strains in their ability to be treated by oseltamivir.", "The investigators suggested that multiple factors can contribute to the efficacy of neuraminidase inhibitors against highly pathogenic H5N1 influenza viruses in vivo, such as virus virulence, virus neurotropic potential, high levels of pulmonary expression of pro-inflammatory chemokines and cytokines, and pre-existing minor populations of drug-resistant clones."], ["Much work has been performed to evaluate compounds used in combination, some of which involved testing of drug-resistant viruses.", "However, these efforts have primarily focused on using amantadine-resistant viruses that are readily obtainable and many of which were easily mouse adapted.", "From the results of these studies, the infection of mice with mouse-adapted influenza A/MS-H275Y virus appears to represent a useful model for studying the treatment of oseltamivir-resistant virus infections with newly discovered antiviral substances and compounds used in combination.", "The A/HK-H275Y model is also useful but we found that variable mortality occurred from experiment to experiment.", "Since the A/HK-H275Y virus is resistant to oseltamivir and to adamantanes, it offers more limited possibilities for combina tion treatment than the A/MS-H275Y virus.", "The A/MS-H275Y virus has already shown to be synergistically inhibited in vitro by the combination of oseltamivir carboxylate, amantadine, and ribavirin.", "It will be important to investigate such combinations in mouse models of oseltamivir-resistant virus infection."]]}]}